

Modifiable Major Risk Factors

Atherosclerosis • Mechanisms, vascular pathology, and risk integration

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraisakhri.com

Learning objectives

- Distinguish modifiable from constitutional atherosclerotic risk factors.
- Explain how LDL, vascular injury, smoking, diabetes, and inflammation promote atherogenesis.
- Relate risk-factor control to plaque progression and major clinical complications.
- Interpret textbook risk estimates without confusing distinct endpoints.

Atherosclerosis is the disease context

Major modifiable exposures converge on an intimal plaque

- Atheromas contain lipids, inflammatory cells, smooth muscle cells, and extracellular matrix.
- Plaques may narrow the lumen or undergo disruptive change followed by thrombosis.
- Clinical territories include coronary, cerebral, and peripheral arteries.

Modifiable versus constitutional risk

Potentially modifiable

- Hyperlipidemia
- Hypertension
- Cigarette smoking
- Diabetes and its metabolic effects
- Inflammation: Mechanistic target/context


Constitutional

- Genetic susceptibility and family history
- Increasing age
- Sex-related risk patterns
- Neither category acts in isolation
- Risk management remains relevant at any baseline risk

The major risk-factor framework

- Lipid abnormalities, hypertension, cigarette smoking, and diabetes as major modifiable risks.
- The chapter's risk-factor table also lists inflammation under modifiable factors.
- Systemic risk factors act within a locally susceptible arterial wall.
- Risk factors often act synergistically rather than independently.

From systemic exposure to vascular disease



Multiple exposures can converge on common pathways; No single factor determines every lesion.

Why risk factors matter before symptoms


Lesion development precedes many clinical events

- Atherosclerosis is progressive and may be clinically silent for years.
- An obstructive plaque limits perfusion; A disrupted plaque can precipitate thrombosis.
- Risk reduction can mitigate risk even when elimination of exposure is incomplete.

Lipid abnormalities: The central risk factor

- Hyperlipidemia, especially hypercholesterolemia, is a major atherosclerosis risk factor.
- Hypercholesterolemia alone can initiate lesion development in the absence of other risks.
- LDL cholesterol is the serum-cholesterol component most strongly linked to increased risk.
- Circulating lipoprotein concentrations and composition both matter.

How LDL delivers cholesterol




LDL is a protein–lipid–cholesterol complex that transports cholesterol to peripheral tissues.

Evidence that LDL is atherogenic

- Cholesterol and cholesterol esters dominate the lipid component of plaques.
- Inherited defects of lipoprotein uptake can accelerate atherosclerosis.
- Population analyses link increasing LDL or total cholesterol with greater lesion burden.
- Reducing serum cholesterol slows progression and lowers cardiovascular event risk.

How LDL becomes trapped within arteries




Modified LDL uptake fosters lipid-laden foam cells and an inflammatory response.

LDL oxidation and local injury

- Reactive oxygen species can promote LDL oxidation within the intima.
- Modified LDL is toxic to endothelial cells and other arterial-wall cells.
- Macrophage uptake uses scavenger receptors, distinct from the conventional LDL receptor.
- Persistent uptake contributes to intracellular lipid accumulation.

Where circulating LDL becomes plaque lipid




LDL retained in the intima

Lipid-rich plaque core

Plaque encroaches on lumen

Underlying arterial media

Foam-cell formation creates early lesions



Foam cells may derive from macrophages; Vascular smooth muscle cells may also accumulate lipids.

LDL receptor versus scavenger uptake

Conventional LDL uptake

- LDL receptor mediates uptake of circulating LDL.
- Hepatic receptor function is key to LDL clearance.
- Defective receptor function elevates LDL levels.

Modified-lipid uptake

- Macrophages use scavenger receptors for altered LDL.
- Sustained modified-lipid ingestion produces foam cells.
- The cell response contributes to local inflammation.

Familial LDL-receptor dysfunction


An inherited risk factor exposes the causal role of LDL

- Loss-of-function LDL-receptor mutations diminish hepatic uptake and catabolism.
- Severe receptor defects lead to markedly elevated LDL and accelerated atherosclerosis.
- This mechanism links genetic susceptibility to a treatable lipid phenotype.

HDL: Reverse cholesterol transport

- HDL mobilizes cholesterol from peripheral tissues, including atheromas.
- It transports cholesterol to the liver for catabolism and biliary excretion.
- Higher circulating HDL levels correlate with lower cardiovascular risk.
- Association between HDL concentration and risk does not alone establish a therapeutic target.

Reverse cholesterol transport concept



HDL's role contrasts with LDL delivery of cholesterol to peripheral tissues.

LDL and HDL have different roles

LDL cholesterol

- Delivers cholesterol to peripheral tissues.
- Elevated LDL is causally linked to plaque development.
- Lowering LDL is associated with fewer events.

HDL cholesterol

- Mobilizes cholesterol from peripheral tissues.
- Higher HDL level correlates with lower risk.
- Exclusively raising HDL has not yielded expected benefit.

HDL: A biomarker is not always a target

Raising HDL concentration alone is not an effective strategy

- Higher HDL levels associate with less risk, but correlation need not imply that increasing HDL concentration reduces events.
- Ineffective HDL-raising approaches with demonstrated LDL-lowering benefits.
- Avoid equating favorable laboratory change with proven clinical benefit.

Dyslipoproteinemia is heterogeneous

- Increased LDL cholesterol is the dominant lipid-associated major risk factor.
- Low HDL can be part of an atherogenic lipid phenotype.
- The adjacent pathogenesis section also describes elevated lipoprotein(a).
- Secondary disorders may influence lipid patterns, including diabetes and hypothyroidism.

Dietary lipids: The source's distinctions

Textbook-described favorable feature

- Omega-3 fatty acids are considered beneficial.
- Overall diet effects should not be reduced to one nutrient.
- Actual risk reduction requires attention to the lipid profile.


Textbook-described unfavorable feature

- Artificially hydrogenated trans-unsaturated fats can worsen cholesterol profiles.
- Most other dietary fat effects as smaller than previously assumed.
- Do not infer drug-equivalent benefits from diet statements.

Intervening on the lipid pathway

- Dietary and pharmacologic LDL-lowering interventions have clinical relevance.
- Lowering cholesterol may slow plaque progression and permit regression of some lesions.
- Effects on cardiovascular events are more important than biomarker changes alone.
- Mechanisms of cholesterol reduction differ among intervention classes.

Statins target cholesterol synthesis




Statins inhibit the rate-limiting enzyme in hepatic cholesterol biosynthesis.

What the textbook attributes to statins


- Statins are widely used to lower circulating cholesterol.
- Their use is associated with reduced rates of myocardial infarction.
- Robbins also considers anti-inflammatory effects as possible contributors to benefit.
- Lipid reduction remains the established therapeutic mechanism discussed here.

PCSK9 drives LDL-receptor degradation



PCSK9 increases degradation of LDL receptors, thereby tending to raise LDL cholesterol.

Blocking PCSK9 lowers LDL



Loss-of-function PCSK9 variants and PCSK9 inhibitors support the receptor-clearance mechanism.

Statin and PCSK9 strategies

Statin strategy

- Primary site: Hepatic synthesis.
- Mechanism: Inhibits HMG-CoA reductase.
- Textbook cites fewer myocardial infarctions.

PCSK9 inhibitor strategy

- Primary site: LDL-receptor fate.
- Mechanism: Prevents PCSK9-driven receptor degradation.
- Textbook cites marked LDL reduction.

Two therapeutic levers for LDL


Production and clearance are distinct control points

- Statin: Reduce hepatic cholesterol biosynthesis.
- PCSK9 inhibition: Preserve LDL receptors and promote receptor-mediated LDL removal.
- Both change LDL biology; The extracted passage provides no dosing or patient-selection algorithm.

Hypertension: A major arterial insult

- Hypertension is a major modifiable risk factor for atherosclerotic disease.
- Chronic pressure stress affects vascular function and promotes arterial injury.
- Endothelial dysfunction facilitates lipoprotein entry and leukocyte recruitment.
- Blood-pressure control is part of multifactorial risk reduction.

Pressure burden and plaque susceptibility



Hypertension contributes alongside lipids and inflammation rather than acting as an isolated plaque pathway.

Hypertension and ischemic heart disease

~60%

Higher ischemic heart disease
risk

**Textbook comparison: Hypertension versus
normotension**

Hypertension can increase the risk by
approximately 60%.

Comparisons are source-specific; These figures are not interchangeable risk metrics.

Left ventricular hypertrophy: Risk context

- Chronic hypertension is the most common cause of left ventricular hypertrophy.
- The hypertrophied ventricle reflects sustained pressure loading.
- Left ventricular hypertrophy as a surrogate marker of cardiovascular risk.
- Hypertrophy should not be confused with an atherosclerotic plaque itself.

Hypertension and the two vascular phenotypes

Atherosclerotic large-vessel disease

- Intimal atheroma formation and complications.
- Hypertension is one contributor among several.
- Clinical consequences include ischemic events.

Hypertensive arteriolar disease

- Small-artery/arteriolar wall changes.
- Hyaline or hyperplastic arteriolosclerosis.
- Can cause parenchymal ischemia, especially renal.


Why coexisting hypertension and dyslipidemia matter

- LDL supplies a substrate for intimal lipid accumulation.
- Hemodynamic stress worsens endothelial susceptibility.
- Inflammatory cell recruitment amplifies lesion progression.
- Addressing only one factor leaves other pathogenic inputs active.

Cigarette smoking: A strong acquired risk

- Prolonged cigarette exposure substantially elevates ischemic heart disease mortality.
- Cigarette-smoke toxins contribute to endothelial dysfunction.
- The duration of exposure matters comparison.
- Smoking cessation materially reduces the associated risk.

Tobacco exposure and the vessel wall



Smoke exposure is one of several contributors to endothelial injury in the response-to-injury framework.

Long-term smoking and IHD mortality

2×

Death rate

Textbook comparison: Prolonged cigarette smoking

An approximately doubled death rate from ischemic heart disease.

Comparisons are source-specific; These figures are not interchangeable risk metrics.

Smoking cessation changes risk

A behavioral exposure is biologically and clinically reversible in part

- Smoking cessation substantially reduces the elevated ischemic heart disease risk.
- Reduction is meaningful even after years of exposure.
- The source passage does not specify a timeline for risk normalization.

Smoking is not just a lipid exposure

- Endothelial toxins act even without isolated hypercholesterolemia.
- Adverse vascular effects intersect with leukocyte adhesion and thrombosis.
- Tobacco and elevated LDL can operate simultaneously.
- Risk-factor inventories should identify smoking independently of lipid measurements.

Exposure assessment versus tissue consequence

Exposure history

- Active cigarette smoking and years of exposure.
- Cessation is a modifiable intervention.
- No safe threshold is established by the supplied passage.


Vascular pathology

- Endothelial dysfunction is a mechanistic connection.
- Intimal inflammation helps plaque progression.
- Clinical event risk reflects multiple concurrent factors.

Diabetes creates an atherogenic milieu

- Diabetes as a major modifiable atherosclerotic risk condition.
- Diabetes can induce hypercholesterolemia and interact with other lipid abnormalities.
- Hyperglycemia is included among stimuli that promote endothelial dysfunction.
- Diabetic vascular risk extends beyond the coronary circulation.

Metabolic disease and intimal injury



The relationship is multifactorial: Lipid alteration and endothelial stress can occur together.

Diabetes and myocardial infarction

2×

Incidence

Textbook comparison: Diabetes versus normoglycemia

All other factors being equal, twice the incidence of myocardial infarction.

Comparisons are source-specific; These figures are not interchangeable risk metrics.

Diabetes extends risk to the brain

Stroke is part of the macrovascular disease burden

- An increased stroke risk in people with diabetes.
- Stroke can reflect atherosclerotic involvement in cerebral arteries.
- Consider coronary, cerebral, and peripheral arterial outcomes separately.

Diabetes and lower-extremity gangrene

100×

Textbook-reported risk

Outcome: Atherosclerosis-induced lower-extremity gangrene

A 100-fold increased risk; The extracted passage does not define the study population.

Comparisons are source-specific; These figures are not interchangeable risk metrics.

Diabetes: Large-vessel versus small-vessel effects

Macrovascular / atherosclerotic

- Accelerated atheroma formation.
- Increased myocardial infarction incidence.
- Increased stroke and ischemic limb complications.

Microvascular / metabolic context

- Hyperglycemia influences vascular tissues.
- Specific microangiopathic complications are outside this unit.
- Do not equate all diabetic vascular injury with atherosclerosis.


A clinical lipid result needs metabolic context

- The same measured LDL level may occur in different clinical risk settings.
- Diabetes is itself a major risk condition, not merely an LDL value.
- Smoking and blood pressure alter the patient's overall risk profile.
- Risk assessment should integrate exposures, diseases, and their interactions.

Inflammation is integral to atherogenesis

- The textbook's major-risk table includes inflammation.
- Activated macrophages and T lymphocytes contribute to plaque progression.
- Cholesterol crystals can activate innate immune inflammatory pathways.
- Inflammatory signaling can amplify endothelial activation and leukocyte recruitment.

Lipid accumulation activates inflammation



Inflammation is both a response to lipids and an amplifier of plaque growth.

Inflammatory markers require interpretation

- CRP is an acute-phase protein primarily produced by the liver.
- CRP as an independent marker of cardiovascular-event risk.
- The text distinguishes risk prediction from a direct causal role for CRP.
- CRP may decline with smoking cessation, weight loss, exercise, or statin use.

Inflammation: Mediator versus marker


Mechanistic mediators

- Macrophage activation and cytokine release.
- Intimal leukocyte recruitment.
- Plaque progression and potential destabilization.

Clinical marker: CRP

- Associates with risk for vascular events.
- Not established as a direct causal factor in this text.
- A measured biomarker is not synonymous with a treatment target.

How risk factors converge in a mature plaque



Fibrous tissue caps the plaque

Cells and cytokines promote growth

Necrotic lipid-rich center

Underlying arterial media


Why the combined risk is substantial

- Conventional factors are not independent biological silos.
- Lipid retention, endothelial dysfunction, and inflammation reinforce one another.
- Risk-factor effects are often more than additive.
- Risk reduction across several domains mitigates cumulative disease burden.

Major factors: Primary pathways

Factor	Major contribution	Key source-linked teaching point
High LDL	Intimal lipid loading	Direct atherogenic role
Hypertension	Endothelial/hemodynamic stress	LV hypertrophy as risk marker
Smoking	Toxic endothelial injury	Cessation lowers risk
Diabetes	Metabolic and endothelial injury	Coronary + peripheral risk
Inflammation	Cell recruitment and signaling	Mechanism $\neq$ CRP causation

The main modifiable pathways



Multiple interventions address different components of atherogenesis; Exact treatment thresholds are outside the source excerpt.

Risk modification is not a guarantee

What intervention can do

- Mitigate cumulative risk.
- Reduce progression and selected events.
- Remove or lower important exposures.
- Target several biologic pathways.

What intervention cannot promise

- Eliminate constitutional susceptibility.
- Reverse every established plaque.
- Guarantee freedom from events.
- Replace comprehensive clinical evaluation.

Case: Isolated severe cholesterol elevation

CLINICAL SCENARIO

A young adult has markedly elevated LDL cholesterol but reports no tobacco use and has no known hypertension or diabetes. A parent experienced premature coronary disease.

Can high LDL alone initiate atherogenesis, and what additional mechanism is suggested?

Case: Elevated pressure and ventricular hypertrophy

CLINICAL SCENARIO

A middle-aged adult has longstanding hypertension and echocardiographic left ventricular hypertrophy. LDL is mildly elevated; Smoking history is negative.

What does the hypertrophy represent, and why is atherosclerotic risk still elevated?

Case: Long smoking exposure

CLINICAL SCENARIO

A patient with many years of cigarette smoking asks whether quitting can still help, despite an established atherosclerotic plaque.

Which source-based risk conclusion is appropriate?

Case: Diabetes with leg ischemia

CLINICAL SCENARIO

A person with diabetes develops exertional leg pain and reduced distal arterial pulses. Lipid measurements are available, but the clinician also considers diabetes-specific vascular risk.

Which major-risk factor is operative, and what clinical territory matters?

Case: Interpreting a high HDL value

CLINICAL SCENARIO

A patient's HDL concentration increased after an intervention, but LDL remains elevated. The intervention has not demonstrated a reduction in cardiovascular events.

Why is an HDL increase insufficient evidence of benefit?

Synthesis: Substrate, injury, and amplification

Atherosclerosis is produced by interacting processes

- Lipid: Retained and modified LDL supplies plaque cholesterol.
- Injury: Pressure, smoke toxins, and metabolic disease influence the endothelium.
- Inflammation: Recruited cells and mediators amplify lesion progression.

Recap: Exposure and intervention

Risk exposure or condition

- Elevated LDL cholesterol
- High blood pressure
- Cigarette smoking
- Diabetes

Source-grounded modification

- LDL-lowering therapies and dietary measures
- Blood-pressure control
- Smoking cessation
- Control of the metabolic disorder

Final clinicopathologic points

- Hypercholesterolemia is capable of initiating atherosclerosis even without other classic risks.
- Hypertension, smoking, and diabetes add substantial vascular risk through distinct but overlapping mechanisms.
- Statin and PCSK9 pathways illustrate two LDL-lowering mechanisms.
- Risk estimates refer to different endpoints; Integrate them clinically rather than multiplying them.

Primary reference and scope

Robbins, Cotran & Kumar: Pathologic Basis of Disease

11th edition (2026), Chapter 11: Blood Vessels

Modifiable Major Risk Factors, pp. 449–451

Mechanistic context: adjacent atherosclerosis risk-factor and pathogenesis sections